Business Milestones
2025.04.02
TAHO Pharmaceuticals Receives Patent Grant from the New Zealand Patent Office for TAH3311 Apixaban Anticoagulant Oral Dissolving Film
Taipei — April 1, 2025 – TAHO Pharmaceuticals announced that the Intellectual Property Office of New Zealand has granted its patent application for "Apixaban Film Product and Uses Thereof." This milestone secures patent protection for a novel, film-based formulation of Apixaban, an anticoagulant commonly used to prevent and treat blood clots. The patent further underscores TAHO Pharmaceuticals’ commitment to developing innovative drug delivery solutions that enhance patient care and convenience.
This unique formulation transforms Apixaban into a gentle film that melts in the mouth, no water needed. Unlike traditional tablets, it’s a kinder, easier way to heal, crafted especially for stroke survivors, seniors, and kids who struggle to swallow. It lightens the load for caregivers too, bringing relief to those who need it most.
About TAH3311
TAH3311, the world’s first Apixaban oral dissolving film (ODF), is a groundbreaking product developed by TAHO Pharmaceuticals Ltd. Utilizing TAHO’s proprietary Transepithelial Delivery System (TDS), TAH3311 dissolves instantly in the mouth without the need for water, providing a convenient, user- friendly experience for stroke survivors, the elderly, and others who face challenges swallowing pills.
Proven bioequivalent to Eliquis® in pivotal clinical studies, TAH3311 is prepared for regulatory submissions to the FDA and EMA. With millions of patients requiring blood thinners annually—and over $26 billion spent in the U.S. alone (Source: IQVIA)—TAH3311 aims to deliver simpler, more compassionate care worldwide.
This unique formulation transforms Apixaban into a gentle film that melts in the mouth, no water needed. Unlike traditional tablets, it’s a kinder, easier way to heal, crafted especially for stroke survivors, seniors, and kids who struggle to swallow. It lightens the load for caregivers too, bringing relief to those who need it most.
About TAH3311
TAH3311, the world’s first Apixaban oral dissolving film (ODF), is a groundbreaking product developed by TAHO Pharmaceuticals Ltd. Utilizing TAHO’s proprietary Transepithelial Delivery System (TDS), TAH3311 dissolves instantly in the mouth without the need for water, providing a convenient, user- friendly experience for stroke survivors, the elderly, and others who face challenges swallowing pills.
Proven bioequivalent to Eliquis® in pivotal clinical studies, TAH3311 is prepared for regulatory submissions to the FDA and EMA. With millions of patients requiring blood thinners annually—and over $26 billion spent in the U.S. alone (Source: IQVIA)—TAH3311 aims to deliver simpler, more compassionate care worldwide.